Marilena V Iorio

List of Publications by Citations

52 papers	19,622 citations	29 h-index	65 g-index
65 ext. papers	20,998 ext. citations	7.7 avg, IF	6.4 L-index

#	Paper	IF	Citations
52	A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 2257-61	11.5	4710
51	MicroRNA gene expression deregulation in human breast cancer. *Cancer Research*, **2005**, 65, 7065-70	10.1	3315
50	miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13944-9	11.5	2912
49	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *New England Journal of Medicine*, **2005**, 353, 1793-801	59.2	2041
48	MicroRNA signatures in human ovarian cancer. *Cancer Research*, **2007**, 67, 8699-707	10.1	1251
47	MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Molecular Medicine*, **2012**, 4, 143-59	12	1200
46	MicroRNAs in cancer: small molecules with a huge impact. *Journal of Clinical Oncology*, **2009**, 27, 5848-56	2.2	813
45	microRNA involvement in human cancer. *Carcinogenesis*, **2012**, 33, 1126-33	4.6	451
44	microRNA-205 regulates HER3 in human breast cancer. *Cancer Research*, **2009**, 69, 2195-200	10.1	298
43	Reprogramming of miRNA networks in cancer and leukemia. *Genome Research*, **2010**, 20, 589-99	9.7	287
42	MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. *Journal of the National Cancer Institute*, **2010**, 102, 706-21	9.7	269
41	Interplay between microRNAs and the epigenetic machinery: an intricate network. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2010**, 1799, 694-701	6	229
40	Causes and consequences of microRNA dysregulation. *Cancer Journal (Sudbury, Mass)*, **2012**, 18, 215-22	2.2	212
39	Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. *Cell Death and Disease*, **2016**, 7, e2312	9.8	174
38	Role of HER receptors family in development and differentiation. *Journal of Cellular Physiology*, **2004**, 200, 343-50	7	168
37	MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. *European Journal of Cancer*, **2008**, 44, 2753-9	7.5	123
36	Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. *Molecular Oncology*, **2012**, 6, 458-72	7.9	122

35	Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. *PLoS Genetics*, **2013**, 9, e1003311	6	117
34	WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. *Oncogene*, **2019**, 38, 4047-4060	9.2	101
33	Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. *Cancer Letters*, **2017**, 384, 94-100	9.9	96
32	Breast cancer and microRNAs: therapeutic impact. *Breast*, **2011**, 20 Suppl 3, S63-70	3.6	80
31	miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. *Cancer Research*, **2016**, 76, 5562-72	10.1	67
30	MicroRNAs and triple negative breast cancer. *International Journal of Molecular Sciences*, **2013**, 14, 22202-30	3.3	59
29	miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. *Oncotarget*, **2016**, 7, 786-97	3.3	56
28	Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer. *Scientific Reports*, **2018**, 8, 12252	4.9	45
27	UCbase & miRfunc: a database of ultraconserved sequences and microRNA function. *Nucleic Acids Research*, **2009**, 37, D41-8	20.1	35
26	PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. *Molecular Oncology*, **2014**, 8, 968-81	7.9	32
25	HER2 signaling enhances 5′UTR-mediated translation of c-Myc mRNA. *Journal of Cellular Physiology*, **2004**, 200, 82-8	7	29
24	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. *Clinical Cancer Research*, **2019**, 25, 3887-3895	12.9	22
23	Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. *Cancers*, **2019**, 11,	6.6	21
22	Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation. *PLoS ONE*, **2013**, 8, e58849	3.7	19
21	Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. *Molecular Oncology*, **2019**, 13, 909-927	7.9	19
20	MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	18
19	Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas. *International Journal of Cancer*, **2014**, 135, 2034-45	7.5	14
18	Relationship between p53 and p27 expression following HER2 signaling. *Breast*, **2007**, 16, 597-605	3.6	13

17	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
16	MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. *Oncotarget*, **2018**, 9, 27920-27928	3.3	12
15	The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. *BMC Cancer*, **2018**, 18, 586	4.8	11
14	MicroRNA profiling in ovarian cancer. *Methods in Molecular Biology*, **2013**, 1049, 187-97	1.4	8
13	miR-205 in Breast Cancer: State of the Art. *International Journal of Molecular Sciences*, **2020**, 22,	6.3	8
12	MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer. *Cancers*, **2020**, 12,	6.6	7
11	Mexican Extracts Decrease Lipogenesis Modulating Transcriptional Metabolic Networks and Gut Microbiota in C57BL/6 Mice Fed with a High-Cholesterol Diet. *Nutrients*, **2020**, 13,	6.7	6
10	miR-9-Mediated Inhibition of Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts. *Cells*, **2020**, 9,	7.9	6
9	MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. *Breast*, **2018**, 39, 46-52	3.6	5
8	The Therapeutic Potential of MicroRNAs in Cancer: Illusion or Opportunity?. *Pharmaceuticals*, **2020**, 13,	5.2	5
7	Commentary on microRNA Fingerprint in Human Epithelial Ovarian Cancer. *Cancer Research*, **2016**, 76, 6143-6145	10.1	5
6	Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. *Cancers*, **2021**, 13,	6.6	2
5	Current and Future Developments in Cancer Therapy Research: miRNAs as New Promising Targets or Tools **2012**, 517-546		1
4	What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.. *Cancer Medicine*, **2021**,	4.8	1
3	Control of Receptor Function by MicroRNAs in Breast Cancer **2013**, 287-310		
2	Pathophysiology rolesr and translational opportunities of miRNAs in breast cancer **2022**, 195-201		
1	Worldwide SARS-CoV-2 haplotype distribution in early pandemic.. *PLoS ONE*, **2022**, 17, e0263705	3.7	